ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ICP-322

A development code.

Its studies are mostly in Prurigo, led by InnoCare Pharma.

Furthest: phase 2, since Oct 27, 20251 company-led study, 1 open or runningNext primary completion: Mar 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
InnoCare Pharma11 open or runningphase 2since Oct 27, 2025Oct 27, 2025Mar 2027phase 2 · NCT07236099

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 27, 2025First study: phase 2 study in Prurigo Nodularis (PN)First studyNCT07236099 · 135 planned · United States, China, France and more

Ahead

  1. Mar 2027Primary completion: phase 2 study in Prurigo Nodularis (PN)NCT07236099

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07236099Prurigo Nodularis (PN) · United States, China, France and more2RecruitingMar 2027135

How it is read

Names in the registry

  • “ICP-322”, 1 entry

Codes read as this program: ICP322.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.